Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Role of basal calcium in the EGF activation of MAP kinases

Oncogene volume 19, pages 1853–1856 (2000)Cite this article

Abstract

The role of intracellular Ca2+ pools in the regulation of growth factor signal transduction pathways and mitogenesis is not well understood. We have examined the roles of basal and transiently mobilized Ca2+ in the regulation of MAP kinases by EGF. To assess the influence of Ca2+ transients we utilized Plcg1−/− and Plcg1+/+ mouse embryonic fibroblasts, while BAPTA/AM was employed to chelate total intracellular Ca2+ in the same cell lines. The MAP kinases erk-1, erk-2 and erk-5 exhibited similar patterns of activation in wild-type and Plcg1−/− cells treated with EGF. However, pretreatment with BAPTA/AM significantly increased and prolonged erk-1 and erk-2 activation in both cell types. In contrast, BAPTA/AM prevented the EGF activation of erk-5 in wild-type and Plcg1−/− cells. These data indicate that basal Ca2+, but not growth factor provoked Ca2+ transients, has a significant influence on the activation of these MAP kinases. AG1478, a specific EGF receptor kinase inhibitor, abolished the prolonged erk-1 and erk-2 activation produced by EGF in cells pretreated with BAPTA/AM. This indicates that the prolonged activation of erk-1 and erk-2 produced in the presence of BAPTA/AM requires continuous signaling from the EGF receptor kinase.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Abe J, Kusukura M, Ulevitck RJ, Berk BC and Lee J-D . 1996 J Biol Chem 271: 16586–16590

  • Berridge MJ . 1995 BioEssays 17: 491–500

  • Berridge MJ and Irvine RF . 1984 Nature 312: 315–321

  • Böhmer F-D, Böhmer A, Obermeier A and Ullrich A . 1995 Anal Biochem 228: 267–273

  • Clapham DE . 1995 Cell 80: 259–268

  • Clements JL, Boerth NJ, Lee JR and Koretzky GA . 1999 Annu Rev Immunol 17: 89–108

  • Cook SJ, Beltman J, Cadwallader KA, McMahon M and McCormick F . 1997 J Biol Chem 272: 13309–13319

  • Dolmetsch RE, Lewis RS, Goodnow CC and Healy JI . 1997 Nature 386: 855–858

  • Dolmetsch RE, Xu K and Lewis RS . 1998 Nature 392: 933–936

  • English JM, Pearson G, Baer R and Cobb MH . 1998 J Biol Chem 273: 3854–3860

  • English JM, Pearson G, Hockenberry T, Shivakumar L, White MA and Cobb MH . 1999 J Biol Chem 274: 31588–31592

  • Guan K-L and Butch E . 1995 J Biol Chem 270: 7197–7203

  • Ji Q-s, Chattopadhyay A, Vecchi M and Carpenter G . 1999 Mol Cell Biol 19: 4961–4970

  • Ji Q-s, Ermini S, Baulida J, Sun F-L and Carpenter G . 1998 Mol Biol Cell 9: 749–757

  • Ji Q-s, Winnier GE, Niswender KD, Horstman D, Wisdom R, Magnuson MA and Carpenter G . 1997 Proc Natl Acad Sci USA 94: 2999–3003

  • Kamakura S, Moriguchi T and Nishida E . 1999 J Biol Chem 274: 26563–26571

  • Kamat A and Carpenter G . 1997 Cytokine Growth Factor Rev 8: 109–117

  • Kato Y, Kiravechenko VV, Tapping RI, Han J, Ulevitch RJ and Lee J-D . 1997 EMBO J 16: 7054–7066

  • Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ and Lee J-D . 1998 Nature 395: 713–716

  • Keyse SM and Emslie EA . 1992 Nature 359: 644–647

  • Levitzki A and Gazit A . 1995 Science 267: 1782–1788

  • Li W-H, Llopis J, Whitney M, Zlokarnik G and Tsien RY . 1998 Nature 392: 936–941

  • Rhee SG and Bae YS . 1997 J Biol Chem 272: 15045–15058

  • Rohan PJ, Davis P, Maskaluk CA, Kearns M, Krutzsch H, Siebervist V and Kelly K . 1993 Science 259: 1763–1766

  • Scimeca J-C, Servant MJ, Dyer J-O and Meloche S . 1997 Oncogene 15: 717–725

  • Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges L, Przybranowski S, Leopold WR and Saltier AR . 1999 Nature Med 5: 810–816

  • Stoscheck CM and Carpenter G . 1983 Arch Biochem Biophys 227: 457–468

  • Treisman R . 1996 Curr Opin Cell Biol 8: 205–215

  • Yan C, Takahashi M, Okuda M, Lee J-D and Berk BC . 1999 J Biol Chem 274: 143–150

  • Zhou G, Bao ZQ and Dixon JE . 1995 J Biol Chem 270: 12665–12669

Download references

Acknowledgements

The authors appreciate the generosity of Dr Jiing-Dwan Lee (Scripps Research Institute) for the gift of antibody to erk-5 and the assistance of Sue Carpenter in preparation of the manuscript. Grant support (CA75195) from the National Institutes of Health is acknowledged.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, 37232-0146, Tennessee, TN, USA

    Qun-sheng Ji & Graham Carpenter

Authors
  1. Qun-sheng Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graham Carpenter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ji, Qs., Carpenter, G. Role of basal calcium in the EGF activation of MAP kinases. Oncogene 19, 1853–1856 (2000). https://doi.org/10.1038/sj.onc.1203517

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203517

Keywords

Search

Advanced search

Quick links